Instructor
Kristen Taylor Meadows Ph.D.
Bio
Kristen Taylor Meadows, Ph.D., is an Immunologist with over 15 years of experience in drug discovery and development, with a focus on autoimmune and inflammatory diseases. She has worked across the biotech and pharmaceutical landscape, from early-stage startups to global pharma, bringing scientific leadership and strategic insight to programs from target validation through clinical development.Dr. Taylor Meadows was part of the team that advanced ozanimod (Zeposia®) to FDA approval for Multiple Sclerosis and Ulcerative Colitis. Her work contributed to the understanding of its mechanism of action, differentiation, biomarker development, and indication expansion. In total, she has contributed to eight IND submissions and one NDA and supported multiple clinical-stage programs including a Phase III asset for Pulmonary Arterial Hypertension and Phase II programs in Crohn’s Disease, Ulcerative Colitis, and Asthma.
She has held senior leadership roles including Vice President of Discovery and Translational Science at Endpoint Health and Senior Director of Biology at Gossamer Bio, where she led the In Vivo Pharmacology Team that supported preclinical and clinical assets. Her areas of expertise include vitro assay development, in vivo pharmacology, translational science, and biomarker strategy.
Dr. Taylor Meadows is currently the Founder and Principal Consultant of KRTM Consulting Services, LLC, where she advises small and mid-sized biotech companies on discovery and early development strategy, including experimental design, platform development, and scientific positioning.
She holds a B.S. in Biochemistry from the University of Arizona, a Ph.D. in Biomedical Sciences from UC San Diego, and completed her postdoctoral training in Immunology at The Scripps Research Institute. Dr. Taylor Meadows is an active contributor to the scientific community through publications and conference presentations.